This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Retain Charles River Stock in Your Portfolio Now?
by Zacks Equity Research
CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
Should You Hold Quest Diagnostics Stock in Your Portfolio Now?
by Zacks Equity Research
DGX's strength in the base business and the robust adoption of Advanced Diagnostics services bode well.
New Product Offerings Support QIAGEN's Shares Amid Currency Woes
by Zacks Equity Research
To support internal growth, QIAGEN is investing heavily in R&D for menu expansion of its key platforms.
STERIS Gains From Expanded Product Offerings Amid Macro Issues
by Zacks Equity Research
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Hold Align Technology Stock in Your Portfolio Right Now?
by Zacks Equity Research
ALGN stock stays on investors' radar, courtesy of its strong Invisalign potential and success with iTero.
Labcorp's New Alliance With Graves Gilbert Clinic Set to Boost Stock
by Zacks Equity Research
LH announces strategic agreement with Graves Gilbert Clinic for lab operations.
Should Prestige Consumer Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
Investors remain optimistic about PBH stock due to its strong focus on brand building.
Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?
by Zacks Equity Research
Via an agreement with the CDC, Hologic is set to develop ASRs for launching the H5N1 bird flu test.
Align Shares Down on Macroeconomic Issues, ASP Challenges
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This results in a decline in the company's revenues.
Should You Retain Teleflex Stock in Your Portfolio Right Now?
by Zacks Equity Research
TFX stays on investors' radars due to its performance in the Vascular Access segment and expansion moves.
Bruker Adds Another 1.2 GHz NMR System in Switzerland, Stock Climbs
by Zacks Equity Research
Bruker announces a 1.2 GHz NMR spectrometer at the Swiss High-field NMR facility.
MYGN Stock Might Gain From the New Recognition of RiskScore Study
by Zacks Equity Research
The American Journal of Human Genetics names Myriad Genetics' RiskScore study as one of the top 10 significant advances in genomic medicine.
Labcorp Launches H5 Bird Flu Test Amid US Outbreak: Stock to Gain?
by Zacks Equity Research
LH's new H5 bird flu test, developed in collaboration with the CDC, is now available in the United States.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about HSIC owing to the performance of its dental business.
ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker
by Zacks Equity Research
Abbott completes the world's first leadless pacing procedures in the left bundle branch of the heart.
Bioproduction Prospects to Drive TMO Shares Despite Macroeconomic Woes
by Zacks Equity Research
TMO's recent strategic acquisitions, including the $3.1-billion acquisition of Olink Holdings, are likely to drive future growth.
LH Stock May Gain From Select MAWD Pathology Asset Purchase Deal
by Zacks Equity Research
Labcorp is set to acquire select assets of MAWD Pathology Group.
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?
by Zacks Equity Research
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Teleflex Expands CVC Portfolio in EMEA With New Launch: Stock to Gain?
by Zacks Equity Research
Teleflex introduces the Arrowg+ard Blue Plus MSB Procedure Kit in the EMEA.
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
by Zacks Equity Research
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?
by Zacks Equity Research
TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay.
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues
by Zacks Equity Research
IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth.